Madrigal Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
First Profitable Quarter Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL)
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633
Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743
Madrigal Q3 Earnings: Why I'm Upgrading The Stock Again In 2026, This Time To Buy
Madrigal Pharmaceuticals Inc (MDGL) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...
MDGL Stock Hits Fresh 52-Week Low On Near-Term Profitability Concerns, But Citi Sees Over 75% Upside
Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760
Loading...